Login to Your Account



Clinic Roundup


Friday, December 17, 2010
• Neuralstem Inc., of Rockville, Md., said the FDA approved its investigational new drug application for a Phase Ia trial of NSI-189, a small molecule designed to stimulate new neuron growth in the hippocampus for treating major depression. The study will test a single dose of the drug in healthy patients. If safety endpoints are met, the trial will move to a Phase Ib portion, testing the safety of escalating doses of daily administration for 28 days in depressed patients. The entire Phase I trial is expected to take about one year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription